Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Johnson on the Risks and Benefits Associated with Anti–PD-1 Therapy in Melanoma

March 31st 2021

Douglas B. Johnson, MD, discusses the risks and benefits associated with anti–PD-1 therapy in patients with stage III resected melanoma.

HEPZATO Demonstrates Promising Preliminary Activity in Metastatic Ocular Melanoma

March 31st 2021

HEPZATO KIT has demonstrated statistically significant benefit compared to best alternative care in patients with liver-dominant metastatic ocular melanoma, according to preliminary results from the phase 3 FOCUS trial.

Dr. Davies on the Potential Role of Novel BRAF Inhibitors in Melanoma Brain Metastases

March 22nd 2021

Michael A. Davies, MD, PhD, discusses the potential role of novel BRAF inhibitors in treating patients with melanoma and brain metastases.

Tilsotolimod/Ipilimumab Fails to Improve ORR in PD-1 Refractory, Advanced Melanoma

March 19th 2021

The combination of tilsotolimod plus ipilimumab failed to improve objective response rate over ipilimumab alone in patients with advanced melanoma who are refractory to a PD-1 inhibitor, missing the primary end point of the phase 2 ILLUMINATE-301 trial.

FDA Grants Orphan Drug Designation to LNS8801 for Metastatic Uveal Melanoma

March 11th 2021

The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.

FDA Grants Orphan Drug Designation to Cavrotolimod for Merkel Cell Carcinoma

March 5th 2021

The FDA has granted an orphan drug designation to cavrotolimod for the treatment of patients with Merkel cell carcinoma.

Dr. Atkins on the Efficacy of Dabrafenib/Trametinib in BRAF-Mutated Melanoma

March 1st 2021

Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.

NeoVax Demonstrates Long-Lasting Durable Responses in Melanoma

February 26th 2021

Neoantigen long peptide vaccines continued to show durable T-cell responses in patients with high-risk melanoma that persisted 4 years after initial vaccination.

Dr. Gibney on Determining Optimal Treatment Duration With Anti–PD-1 Agents in Melanoma

February 26th 2021

Geoffrey T. Gibney, MD, discusses efforts made to determine the optimal duration of treatment with anti–PD-1 agents in patients with melanoma.

Dr. Davies on the Utility of Retreatment With BRAF/MEK Inhibitors in BRAF-Mutant Melanoma

February 24th 2021

Michael A. Davies, MD, PhD, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.

Combos Lead Excitement in BRAF+ Melanoma, But More Pain Points Are Ready to Be Tackled

February 18th 2021

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

Dr. Davies on Selecting Between Combination Regimens in BRAF-Mutant Melanoma

February 17th 2021

Michael A. Davies, MD, PhD, discusses factors to consider when selecting between combination regimens in BRAF-mutant melanoma.

Neoadjuvant Tavokinogene Telseplasmid Plus Nivolumab Under Evaluation in Advanced Melanoma

February 17th 2021

The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid in combination with nivolumab as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

February 9th 2021

February 9, 2021 - The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

Dr. Sullivan on Future of Triplet Therapies in Melanoma

February 9th 2021

Ryan Sullivan, MD, discusses the future of triplet therapies for patients with melanoma.

Future Directions in Metastatic Melanoma

February 5th 2021

Dr. Kudchadkar on Future Research Directions for Rare, Non-Melanoma Skin Cancers

February 2nd 2021

Ragini Kudchadkar, MD, discusses future research directions for patients with rare, non-melanoma skin cancers.

Looking at Approved Agents in Metastatic Melanoma

January 29th 2021

Metastatic Melanoma Treatment Decisions

January 29th 2021

Toripalimab Granted FDA Fast Track Status for Mucosal Melanoma

January 25th 2021

January 25, 2021 - The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.